[go: up one dir, main page]

MA53671A - Formes cristallines d'un agoniste du récepteur farnésoïde x - Google Patents

Formes cristallines d'un agoniste du récepteur farnésoïde x

Info

Publication number
MA53671A
MA53671A MA053671A MA53671A MA53671A MA 53671 A MA53671 A MA 53671A MA 053671 A MA053671 A MA 053671A MA 53671 A MA53671 A MA 53671A MA 53671 A MA53671 A MA 53671A
Authority
MA
Morocco
Prior art keywords
farnesoid
receptor agonist
crystalline forms
crystalline
forms
Prior art date
Application number
MA053671A
Other languages
English (en)
Inventor
Robert Mansfield
Nicholas D Smith
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of MA53671A publication Critical patent/MA53671A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053671A 2018-09-18 2019-09-17 Formes cristallines d'un agoniste du récepteur farnésoïde x MA53671A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862733007P 2018-09-18 2018-09-18

Publications (1)

Publication Number Publication Date
MA53671A true MA53671A (fr) 2021-07-28

Family

ID=69887984

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053671A MA53671A (fr) 2018-09-18 2019-09-17 Formes cristallines d'un agoniste du récepteur farnésoïde x

Country Status (15)

Country Link
US (1) US20210347736A1 (fr)
EP (1) EP3852749A4 (fr)
JP (1) JP2022500395A (fr)
KR (1) KR20210064261A (fr)
CN (1) CN113056270A (fr)
AU (1) AU2019344905A1 (fr)
BR (1) BR112021004931A2 (fr)
CA (1) CA3112485A1 (fr)
CL (1) CL2021000631A1 (fr)
EA (1) EA202190663A1 (fr)
IL (1) IL281464A (fr)
MA (1) MA53671A (fr)
MX (1) MX2021003083A (fr)
SG (1) SG11202102586RA (fr)
WO (1) WO2020061115A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016323992B2 (en) 2015-09-16 2021-05-06 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
WO2020061113A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
EP4121012A1 (fr) * 2020-03-18 2023-01-25 Metacrine, Inc. Formulations d'un agoniste du récepteur farnésoïde x
WO2022094816A1 (fr) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Formulation solide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1914205A (zh) * 2003-12-19 2007-02-14 葛兰素集团有限公司 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
ES2609395T5 (es) * 2004-03-12 2021-08-06 Intercept Pharmaceuticals Inc Tratamiento de la fibrosis usando ligandos de Fxr
JP2010517931A (ja) * 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ, インコーポレイテッド Fxr媒介性の疾患または状態の予防または治療用のfxrリガンドとしての胆汁酸誘導体
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
EP2393811A1 (fr) * 2009-02-04 2011-12-14 Pfizer Inc. Dérivés de 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one
CN103391937A (zh) * 2010-12-20 2013-11-13 Irm责任有限公司 用于调控法尼醇x受体的组合物和方法
JP2018532772A (ja) * 2015-09-16 2018-11-08 メタクリン,インク. ファルネソイドx受容体アゴニストおよびそれらの使用
AU2016323992B2 (en) * 2015-09-16 2021-05-06 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
WO2017049176A1 (fr) * 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
EP3350158A4 (fr) * 2015-09-16 2019-05-08 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
MX389514B (es) * 2015-10-01 2025-03-20 Firmenich Incorporated Compuestos útiles como moduladores de canal receptor 8 de potencial transitorio de melastatina (trpm8).
WO2017078928A1 (fr) * 2015-11-06 2017-05-11 Salk Institute For Biological Studies Agonistes de fxr et procédés de production et d'utilisation
US20200131129A1 (en) * 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170182A1 (fr) * 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations

Also Published As

Publication number Publication date
AU2019344905A1 (en) 2021-04-29
SG11202102586RA (en) 2021-04-29
CA3112485A1 (fr) 2020-03-26
EP3852749A4 (fr) 2022-08-24
JP2022500395A (ja) 2022-01-04
CL2021000631A1 (es) 2021-10-01
WO2020061115A1 (fr) 2020-03-26
MX2021003083A (es) 2021-05-27
KR20210064261A (ko) 2021-06-02
EP3852749A1 (fr) 2021-07-28
EA202190663A1 (ru) 2021-08-13
US20210347736A1 (en) 2021-11-11
IL281464A (en) 2021-04-29
BR112021004931A2 (pt) 2021-06-01
CN113056270A (zh) 2021-06-29

Similar Documents

Publication Publication Date Title
MA53671A (fr) Formes cristallines d'un agoniste du récepteur farnésoïde x
EP3965765A4 (fr) Promédicaments d'antagonistes du récepteur opioïde
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
DK3810201T3 (da) GIP/GLP1-agonist-sammensætninger
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
EP3870178A4 (fr) Formes cristallines d'inhibiteurs de mnk
MA47596A (fr) Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan
EP3870181A4 (fr) Formes cristallines d'un inhibiteur d'alk2
EP3619208C0 (fr) Formes cristallines d'un composé inhibiteur de jak
DK3746609T3 (da) Tilslutningsindretning for en toiletkumme
IL283314A (en) Mutated piggybac transposase
EP4076492A4 (fr) Composés antagonistes du pcsk
MA56001A (fr) Formes de sel cristallin d'un inhibiteur de kinase
MA54638A (fr) Formes cristallines d'un stimulateur de sgc
EP3853597A4 (fr) Amortissement acoustique pour dispositifs d'imagerie à ultrasons
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
EP3863629A4 (fr) Promédicaments d'antagonistes du cgrp
EP4037677A4 (fr) Antagonistes du récepteur m4 d'acétylcholine muscarinique
MA54541A (fr) Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées
EP4006033A4 (fr) Antagoniste du récepteur de l'adénosine
EP3996707A4 (fr) Formes cristallines d'inhibiteurs de la kallicréine plasmatique
IL281168A (en) Crystal forms of the quinazole compound and its hydrochloride salts
EP3897660A4 (fr) Nouvelles formes cristallines d'un composé de nrtti
EP3902545A4 (fr) Nouveaux sels d'agents de dégradation sélectifs du récepteur des oestrogènes
DK3523310T3 (da) Krystallinske polymorfer af en muscarinacetylcholinreceptoragonist